Comparative Pharmacology
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEBCIN versus NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE.
NEBCIN vs NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, causing misreading of mRNA and inhibiting bacterial protein synthesis.
Neomycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis. Polymyxin B is a cationic detergent antibiotic that disrupts bacterial cell membrane integrity by interacting with phospholipids. Hydrocortisone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
3-6 mg/kg/day IV in 2-3 divided doses every 8-12 hours; adjust based on serum levels and renal function.
Instill 3 to 4 drops into the affected ear(s) 3 to 4 times daily. For otic suspension in adults.
None Documented
None Documented
Terminal elimination half-life is 2-3 hours in patients with normal renal function. Prolonged to 24-48 hours in anuria. Clinical context: Dosing interval adjustment required in renal impairment to avoid toxicity.
Neomycin: 2-3 hours (in adults with normal renal function); may accumulate in renal impairment. Polymyxin B: 6-8 hours (prolonged in renal impairment: up to 36 hours). Hydrocortisone: 1.2-1.5 hours (terminal).
Renal excretion of unchanged drug accounts for >90% of elimination. Approximately 10% is excreted in bile.
Neomycin: >90% unchanged in feces after oral administration; negligible renal excretion. Polymyxin B: 60% renal excretion of unchanged drug; remainder nonrenal. Hydrocortisone: primarily hepatic metabolism, <5% renal excretion unchanged.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic